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Aims: Chronic kidney disease is a signiﬁcant risk factor for several comorbidities and death. The longi-
tudinal change in renal function after nephroureterectomy in patients with upper tract urothelial car-
cinomas and the risk of developing chronic kidney disease (CKD) was investigated.
Materials and methods: This retrospective study included 186 patients who underwent unilateral
nephroureterectomy between 1997 and 2001. Creatinine data prior to and after the surgery were
collected and the estimated Glomerular Filtration Rate (eGFR) were calculated with the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation.
Results: The cohort of 186 patients included 87 men and 99 women with a mean age of 67.2 years.
Preoperative mean eGFR was 41.97 mL/minute/1.73 m2. Eighty six percent of the patients' preoperative
eGFR were <60 mL/minute/1.73 m2. The mean eGFR was 35.85 mL/minute/1.73 m2 at the end of the 5-
year follow up. For the 26 patients with preoperative normal renal function, 17 patients (65.4%) had new
chronic kidney diseases. Ten patients (5.4%) required hemodialysis at the end of the study.
Conclusion: In this study, it was found that the average renal function of the patients with upper tract
urothelial carcinoma is not as good as the general population. More than half of the normal renal
function patients have new onset chronic kidney disease after surgery. For preventing further deterio-
ration of renal function, the implication of partial nephrectomy or segmental ureterectomy for selected
patients with localized urothelial carcinoma should be re-examined. Besides, neoadjuvant chemotherapy
should be considered for those who are not good candidates for local treatment.
Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Chronic kidney disease is a signiﬁcant risk factor for several
comorbidities and death.1 There have been several reports sug-
gesting that the incidence rate of chronic kidney disease is as high
as 26% after radical nephrectomy in patients with renal cell carci-
noma.2 Therefore, current guidelines recommend nephron-sparing
surgery as the standard treatment for early-stage renal cell carci-
noma.3,4 By contrast, radical nephroureterectomy (NUx) with
bladder cuff excision remains a standard treatment in upper tract
urothelial carcinoma (UTUC).5,6
Compared with renal cell carcinoma, UTUC often results in
obstructive uropathy rather than massive nephron loss. As thement of Surgery, Chang Gung
r 5, Fuxing Street, Guishan
g).
ciation. Published by Elsevier Taiwmechanism of renal function deterioration is different, it was pro-
posed that long-term renal function change after renal surgery in
patients with urothelial may be different from those who have
renal cell carcinoma. However, to the best of our knowledge, few
reports have discussed the prevalence of chronic kidney disease in
patients who had received NUx because of UTUC.
The longitudinal change in renal function after NUx in patients
with UTUCs was investigated and the new onset chronic kidney
diseases in this patient group were examined. The ﬁndings are
discussed in terms of the implications of nephron-sparing surgery.2. Materials and methods
2.1. Patient selection
After obtaining the approval of the Institutional Review Board of
Chang-Gung Memorial Hospital, clinical data on patients withan LLC. Open access under CC BY-NC-ND license.
Table 1
Baseline characteristics.
Patients, n 186
Mean age (y) 67.20 (37, 88)
Mean follow-up time (y) 4.24 (0.60, 12.67)
Patients, n
Sex
Male 87
Female 99
BMI 24.63 (13.17, 47.44)
Smoking 38 (20.4)
Medical history
Hypertension 83 (44.6)
Diabetes mellitus 43 (23.1)
Cardiovascular disease 28 (15.1)
ASA classiﬁcation
1 16 (8.6)
2 115 (61.8)
3 55 (29.6)
Surgical procedure
Open surgery 164
Laparoscopic surgery 22
Tumor characteristics
Tumor size 3.64 (0.7, 9.5)
T stage
Ta 39
T1 63
T2 25
T3 45
T4 14
Histology
Inﬁltrative 55
Papillary 131
Grade
Low 87
High 99
Data are presented as n, n (%), or n (min, max).
Fig. 1. Mean eGFR over time. Renal function change in the ﬁrst 5 postoperative years.
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pital, Guishan Township, Taiwan between 1997 and 2001 were
retrospectively reviewed. Of the 312 patients who received NUx,
those with dialysis-dependent status and a solitary kidney prior to
the surgery were excluded, and our analysis was limited to patients
with no known renal parenchymal disease. A total of 186 patients
were enrolled for the ﬁnal analysis.
2.2. Statistical analysis
Preoperative evaluation of the patients included medical his-
tory, physical examination, laboratory studies (including serum
creatinine level), urine routine analysis, chest X-ray, electrocar-
diogram, and abdominal computed tomography or magnetic
resonance imaging. Tumor size was measured using the longest
diameter of the tumor. Pathological staging was based on the 2009
American Joint Committee on Cancer 7th edition TNM staging sys-
tem. The baseline and follow-up data of patients were obtained
from the Institutional Review Board and medical records.
Perioperative renal function was evaluated using the serum
creatinine level and the estimated glomerular ﬁltration rate (eGFR).
eGFR was calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration equation.7 Serum creatinine level was checked
prior to and after surgery and during follow-up in the outpatient
department.
The longitudinal change in renal function after surgery was
investigated, and possible risk factors for postoperative new onset
chronic kidney disease were analyzed, which was deﬁned as an
eGFR level <60 mL/minute/1.73 m2.
Preoperative and postoperative mean eGFR for all patients were
compared using the paired t test. In addition, preoperative and
postoperative incidence of eGFR <60 mL/minute/1.73 m2 was
analyzed. The Chi-square test was used to evaluate the diversity
between the groups. All statistical calculations were two tailed, and
p < 0.05 was deemed signiﬁcant. All statistical analysis was per-
formed using SPSS software (version 20; SPSS Inc., Chicago, IL, USA).
3. Results
Table 1 lists demographic, tumor staging, and renal function
data for the 186 patients enrolled in the analysis. Patients with
UTUC were predisposed to have bad baseline renal function, as
evidenced by the mean preoperative serum creatinine level
(1.65 mg/dL) and mean preoperative eGFR (41.97 mL/minute/
1.73 m2). Most patients (n ¼ 160, 86.0%) had a preoperative eGFR of
<60 mL/minute/1.73 m2. Mean eGFR immediately after NUx was
signiﬁcantly lower than mean preoperative eGFR (41.97 mL/min-
ute/1.73 m2 vs. 35.21 mL/minute/1.73 m2, p < 0.001). During post-
operative Years 1e5, the mean eGFR varied between 31.69 mL/
minute/1.73 m2 and 35.85 mL/minute/1.73 m2 (Fig. 1), but there
was no signiﬁcant change in eGFR during follow-up. These results
indicate that the patient's renal function deteriorated immediately
after the surgery, but stabilized during follow-up.
In this study's database, 160 (86.0%) of the 186 patients had
preoperative chronic kidney disease. This result was consistent
with that of previous literature, which has reported that these
patients' renal function tends to be worse compared with that of
the general population. A previous study reported that the preva-
lence of clinically recognized CKD is 9.83%.11 This could explain the
reason for impaired functions of the unaffected kidney prior to the
surgery. An analysis of the relationship between preoperative
chronic kidney disease and other comorbidities such as diabetes,
hypertension, and coronary artery disease was attempted. How-
ever, we could not detect the trend of the relationship. This may be
because of the small sample size. Besides medical comorbidities,aristolochic acid had been reported to be another factor that would
impair the function of the unaffected kidney prior to the surgery.
Owing to the limitation of this retrospective study, we were unable
to collect adequate data for analysis. By contrast to previous studies,
which only recorded postoperative serum creatinine levels once,
this report followed the longitudinal change of these patients' renal
function. It was observed that the patients' renal function deteri-
orated immediately after surgery. However, no further renal func-
tion deterioration was observed in the following years.
The distribution of each chronic kidney disease stage is shown in
Fig. 2. During the 5-year follow-up, 19 of the 26 patients (73.1%)
with normal preoperative renal function developed chronic kidney
disease after the surgery. For the 186 patients who underwent NUx,
C.-Y. Chou et al. / Urological Science 26 (2015) 115e119 117the 5-year cancer-speciﬁc survival and overall survival rate were
90.2% and 82.6%, respectively (Fig. 3A and B). The comparison be-
tween tumor location and perioperative renal function change is
listed in Table 2. There is a trend that ureter tumors had poor renal
outcome after the surgery. However, no statistical signiﬁcance is
observed.
In this study series, after the 5-year follow-up, 10 patients (5.4%)
required hemodialysis after the surgery. Eight patients were femaleFig. 2. Chronic kidney disease stage over time. Each cluster shows the patient distribution
before the surgery. However, their renal function gradually deteriorated.and themean age at operationwas 63 years. Themean preoperative
eGFR was 12.87 mL/minute/1.73 m2 and the mean time to dialysis
was 2.77 years (Fig. 3C).
4. Discussion
The study's database includes the renal outcome of patients
who retained a solitary kidney after receiving a unilateralof different chronic kidney disease stages. Most patients were in stage 3 of the disease
Fig. 3. Survival of patients with upper tract urothelial carcinoma who had received nephroureterectomy and bladder cuff excision: (A) overall survival; (B) cancer-speciﬁc survival;
(C) survival curve of freedom from hemodialysis. The overall and cancer-speciﬁc survival was calculated. The 5-year overall and cancer-speciﬁc rates are 82.6% and 90.2%
respectively. A total of 10 patients became hemodialysis-dependent at the time of data collection. Cum ¼ cumulative.
C.-Y. Chou et al. / Urological Science 26 (2015) 115e119118nephroureterectomy to treat UTUC. The general belief was that
most people could lead a normal life with only one kidney; how-
ever, this viewpoint has been evolving since Rosenthal et al8 ﬁrst
introduced the concept of nephron-sparing surgery in 1984. In
addition, a decrease in nephron number has been shown to
correlate with the progressive impairment of renal function and
hypertension.9 In the following years, several urologists reported
that nephron-sparing surgery led to a better renal outcome than
radical nephrectomy in treating renal cell carcinoma. However, the
role of nephron-sparing surgery in treating urothelial carcinoma
remains undetermined. To the best of our knowledge, there are few
papers that have discussed this issue. Lane et al10 collected a cohort
of 336 patients and analyzed their perioperative change in renal
function. In their study, the patients' mean preoperative eGFR,
which was 61.7 mL/minute/1.73 m2, deteriorated to 47.9 mL/Table 2
Relationship between tumor location and perioperative renal function.
Tumor location (n) Mea
PreOP D1 D14 1 mo 3 mo
Renal pelvis (104) 41.62 34.56 40.95 34.45 33.45
Renal calyces (20) 43.63 35.05 35.76 34.29 34.16
Ureter (5) 44.64 44.06 51.52 48.34 45.91
Multifocal (57) 41.34 36.06 42.26 34.17 34.10minute/1.73 m2 after surgery. However, they only collected post-
operative serum creatinine data for 3 months, rather than collect-
ing longitudinal data. In addition, this research group used the
abbreviated Modiﬁcation in Diet and Renal Disease (MDRD) study
equation to calculate eGFR. This equation has limited usefulness
because it systematically underestimates measured GFR at higher
values. The Chronic Kidney Disease Epidemiology Collaboration
research group proposed another equation in 2009, which yields
higher eGFR at lower creatinine levels.7
We attempted to determine the group of patients that would
experience a poor renal outcome. There were no signiﬁcant pre-
operative conditions that could be used to predict renal outcome.
As for the 10 patients who required hemodialysis after the surgery,
signiﬁcant predisposing factors (Table 3) were not observed.
However, it was observed that patients whose renal functionn eGFR (mL/min/1.73 m2)
6 mo 1 y 2 y 3 y 4 y 5 y
33.98 35.66 33.36 35.36 32.65 39.14
32.40 29.91 28.71 32.48 33.52 35.71
45.08 30.70 23.21 18.86 17.12 14.94
33.10 31.41 29.93 31.37 34.88 33.42
Table 3
Predisposing factors for postoperative hemodialysis-dependent status.
Hemodialysis required
Yes No
Tumor site Renal pelvis 6 98
Renal calyces 0 20
Ureter 1 4
Multifocal 3 54
Preoperative hydronephrosis Yes 7 84
No 3 92
Hypertension Yes 6 77
No 4 99
Diabetes mellitus Yes 2 41
No 8 135
Coronary artery disease Yes 0 28
No 10 148
Smoking Yes 1 37
No 9 139
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renal outcome compared with other patients. Therefore, careful
observation of this group of patients is suggested.
Themainstream treatment for UTUC is nephroureterectomy and
bladder cuff excision.5,6 In this observation, the renal function will
be damaged even if the patient still has a healthy kidney. Therefore,
these results indicated that maybe radical surgery is an over-
treatment for all patients with upper tract urothelial carcinoma. As
the enrolled patients' preoperative overall renal function was
normal and no signiﬁcant cortex thinning was observed, the split
renal function test is not routinely performed. If nephron-sparing
surgery is taken into consideration, split renal function tests, such
asMAG3 renal scan, may play an important role in decision-making
when treating early-staged upper tract urothelial carcinoma.
However, the data is not sufﬁcient for adequate analysis due to the
limitation of a retrospective study. In previous studies, Lane et al10
observed that 52% of the patients with UTUC had chronic kidney
disease at the time of diagnosis and experienced a median 21%
relative reduction in renal function after receiving NUx. The chronic
kidney disease prevalence rate signiﬁcantly increased to 78% after
the surgery. As renal function deteriorated, these patients were
unable to tolerate full-dose cisplatin-based chemotherapy. As a
result, they suggest that neoadjuvant chemotherapy should be
considered while treating patients with UTUC.10
There are a few limitations in this study. First, this was a single-
center retrospective review; therefore, some cases were lost to
follow-up over time. As a result, the patients' survival rate may not
have been accurately estimated. In addition, the adjuvant therapy
protocols varied and cannot offer a better illustration of oncological
outcome. Further prospective observation is needed to evaluate the
detailed condition of these patients' natural history. The cohort
concluded the renal function change in the patients who received
NUx was because of upper tract urothelial carcinoma. This report is
different from that of the other studies, which only recorded onecreatinine data after the surgery, because a temporal change of the
patients' renal function was offered. During the 5-year follow-up,
most of the patients' renal function worsened. Considering the
possible comorbidities, which may be induced by poor renal
function, local ablative treatment or partial nephrectomy in
selected patients should be considered. As for those patients who
are not suitable for local treatment, neoadjuvant chemotherapy
should be considered as an alternative treatment.
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